Reduce MS activity found during steroid administrationThe Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark conducted a study of adding methylprednisolone in the treatment of multiple sclerosis (MS) patients.

The study involved patients with relapsing-remitting MS and who had the disease for an average of three years. The treatment group received both interferon and methylprednisolone, while the control group received the interferon drug and a placebo. The study lasted for three years and the participants were only seen every three months.

The researchers measured the size of the brain lesions at the initial phase and again after a period of three years. They found that those in the treatment group, their lesions either stayed the same size or it shrunk while the lesions grew in size for those in the control group. The sign of disease activity is measured primarily by the size of the lesion in the brain.

Furthermore, those who received both drugs have fewer incidences of relapses while those receiving interferon only have a 38% higher rate of relapse. In terms of MS disability tests, the treatment group improved slightly higher than the control or placebo group.

These results might be an indication that there is a synergy between the two drugs which can provide more benefits than interferon alone.

According to Science Daily:

“These results indicate that these two drugs may have a synergy when taken together and provide a more beneficial effect on the disease activity,” said study author Mads Ravnborg, MD, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark. “This is a promising finding, as the benefit from interferon is only moderate and not everyone responds fully to the treatment, so anything we can do to boost those results is positive.”